Document:

EX-10.9

 Exhibit 10.9 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED 

BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY 

CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED 

AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENT 

This AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENT (this “Amendment”), entered into as of September 23, 2020 (the
“Amendment Effective Date”), is entered into by and among LianBio, a corporation organized and existing under the laws of the Cayman Islands (“LianBio”), LianBio Licensing LLC, a limited liability company organized
and existing under the laws of Delaware and a wholly-owned subsidiary of LianBio (“Licensee”), and Navire Pharma, Inc. (formerly known as PTP Pharmaceuticals, Inc.), a Delaware corporation (“Company”). LianBio,
Licensee, and Company are each referred to herein individually as a “Party”, and collectively as the “Parties.” 

INTRODUCTION 

WHEREAS, the Parties entered into an Exclusive License Agreement, dated August 9th, 2020
(the “License Agreement”) for the Development, Manufacture, and Commercialization of Licensed Products in the Field in the Territory; 

WHEREAS, LianBio is undergoing a financing involving the sale of preferred shares of LianBio (the “Financing”); and 

WHEREAS, the Parties wish to amend the License Agreement to defer the due date of the upfront payment payable by Licensee to Company
thereunder until after the closing of the Financing; 
 NOW, THEREFORE, in consideration of the premises and the mutual promises and
conditions hereinafter set forth, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, do hereby agree as follows: 

1. Capitalized Terms. Capitalized terms used in this Amendment but not otherwise defined will have the meaning as defined in the License
Agreement. 
 2. Upfront Payment. Section 6.1(a) of the License Agreement is hereby amended and
replaced in its entirety as follows: 
 Upfront Payment. Subject to the terms and conditions of this Agreement, Licensee will pay
Company a non-refundable, non-creditable, and not subject to set-off payment in the amount of [***], which upfront payment will
be due and payable to Company upon the earlier to occur of (i) within [***] following the consummation of the [***] preferred equity financing of LianBio after the Effective Date, in a single transaction or series of related transactions, which
raises gross proceeds to LianBio of at least [***], and (ii) [***]. Licensee shall promptly notify Company of the occurrence of the consummation of [***] such financing. 

3. No Breach and No Late Payment Interest. For clarity, if licensee makes the upfront payment to Company in the amount and within the
time frame provided in Section 2 of this Amendment, Licensee shall be deemed to have timely fulfilled its obligations in relation to the upfront payment under the License Agreement, and Licensee will not be required to pay
any late payment interest on such upfront payment. 
  

 4. No Other Changes. All other original terms and conditions of the License
Agreement, except as specifically amended herein, shall remain in full force and effect. 
 5. Execution in Counterparts; Facsimile
Signatures. This Amendment may be executed in counterparts, each of which counterparts, when so executed and delivered, will be deemed to be an original, and all of which counterparts, taken together, will constitute one and the same instrument
even if the Parties have not executed the same counterpart. Signatures provided by facsimile transmission or in AdobeTM Portable Document Format (pdf) sent by electronic mail will be deemed to
be original signatures. 
 [Remainder of this page intentionally blank.] 

  
 2 

 IN WITNESS WHEREOF, each Party has caused this Agreement to be duly executed by its authorized
representative under seal, in duplicate on the Amendment Effective Date. 
  

	
	NAVIRE PHARMA, INC.
	
	 /s/ Michael Henderson

	Name: Michael Henderson
	Title: CBO BBIO
	
	LIANBIO LICENSING LLC
	
	 /s/ Bing Li

	Name: Bing Li
	Title: CEO
	
	LIANBIO 
	
	 /s/ Bing Li

	Name: Bing Li
	Title: CEO

  

  
 SIGNATURE PAGE OF THE
AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENTEX-10.10

 Exhibit 10.10 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED 

BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY 

CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED 

SECOND AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENT 

This SECOND AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENT (this “Amendment”), entered into as of September 28, 2020 (the
“Amendment Effective Date”), is entered into by and among LianBio, a corporation organized and existing under the laws of the Cayman Islands (“LianBio”), LianBio Licensing LLC, a limited liability company organized
and existing under the laws of Delaware and a wholly-owned subsidiary of LianBio (“Licensee”), and Navire Pharma, Inc. (formerly known as PTP Pharmaceuticals, Inc.), a Delaware corporation (“Company”). LianBio,
Licensee, and Company are each referred to herein individually as a “Party”, and collectively as the “Parties.” 

INTRODUCTION 

WHEREAS, the Parties entered into an Exclusive License Agreement, dated August 9th, 2020
as amended by the Amendment to the Exclusive License Agreement dated September 28, 2020, (together, the “License Agreement”) for the Development, Manufacture, and Commercialization of Licensed Products in the Field in the
Territory; and 
 WHEREAS, the Parties wish to amend the License Agreement to replace Exhibit A to the License Agreement. 

NOW, THEREFORE, in consideration of the premises and the mutual promises and conditions hereinafter set forth, and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, do hereby agree as follows: 

1. Capitalized Terms. Capitalized terms used in this Amendment but not otherwise defined will have the meaning as defined in the License
Agreement. 
 2. New Exhibit A. Exhibit A of the License Agreement is hereby deleted in its entirety and replaced with the
attached Exhibit A. 
 3. No Other Changes. All other original terms and conditions of the License Agreement, except as
specifically amended herein, shall remain in full force and effect. 
 4. Execution in Counterparts; Facsimile Signatures. This
Amendment may be executed in counterparts, each of which counterparts, when so executed and delivered, will be deemed to be an original, and all of which counterparts, taken together, will constitute one and the same instrument even if the Parties
have not executed the same counterpart. Signatures provided by facsimile transmission or in AdobeTM Portable Document Format (pdf) sent by electronic mail will be deemed to be original
signatures. 
 [Remainder of this page intentionally blank.] 

 IN WITNESS WHEREOF, each Party has caused this Agreement to be duly executed by its authorized
representative under seal, in duplicate on the Amendment Effective Date. 
  

	
	NAVIRE PHARMA, INC.
	
	 /s/ Michael Henderson

	Name: Michael Henderson
	Title: BBIO CBO
	
	LIANBIO LICENSING LLC
	
	 /s/ Bing Li

	Name: Bing Li
	Title: CEO
	
	LIANBIO 
	
	 /s/ Bing Li

	Name: Bing Li
	Title: CEO

  

  
 SIGNATURE PAGE OF THE
SECOND AMENDMENT TO THE EXCLUSIVE LICENSE 
 AGREEMENT 

 EXHIBIT A 

[***]EX-10.11

 Exhibit 10.11 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY
CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED 
 THIRD AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENT 

This THIRD AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENT (this “Amendment”), entered into as of December 17, 2020 (the
“Amendment Effective Date”), is entered into by and among LianBio, an exempted company organized under the laws of the Cayman Islands (“LianBio”), LianBio Licensing, LLC, a limited liability company organized and
existing under the laws of the State of Delaware and a wholly-owned subsidiary of LianBio (“Licensee”), and Navire Pharma, Inc. (formerly known as PTP Pharmaceuticals, Inc.), a Delaware corporation (“Company”). LianBio,
Licensee, and Company are each referred to herein individually as a “Party”, and collectively as the “Parties.” 

INTRODUCTION 

WHEREAS, the Parties entered into an Exclusive License Agreement, dated August 9th, 2020,
as amended by the Amendment to the Exclusive License Agreement dated September 23rd, 2020 and the Second Amendment to the Exclusive License Agreement dated September 28th, 2020 (together, the “License Agreement”) for the Development, Manufacture, and Commercialization of Licensed Products in the Field in the Territory; 

WHEREAS, pursuant to the License Agreement, Company and Licensee are to negotiate in good faith and enter into a Pharmacovigilance Agreement
within [***] after the Effective Date, which is on or before [***]; and 
 WHEREAS, the Parties wish to amend the License Agreement to defer
the due date for the entering of the Pharmacovigilance Agreement by the Parties thereunder; 
 NOW, THEREFORE, in consideration of the
premises and the mutual promises and conditions hereinafter set forth, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, do hereby agree as follows:

 1.    Capitalized Terms. Capitalized terms used in this Amendment but not otherwise defined will have the
meaning as defined in the License Agreement. 
 2.    Amendments. The Parties agree that the due date for Company
and Licensee to enter into the Pharmacovigilance Agreement shall be extended to [***]. 
 3.    No Other Changes.
All other original terms and conditions of the License Agreement, except as specifically amended herein, shall remain in full force and effect. 

4.    Execution in Counterparts; Facsimile Signatures. This Amendment may be executed in counterparts, each of
which counterparts, when so executed and delivered, will be deemed to be an original, and all of which counterparts, taken together, will constitute one and the same instrument even if the Parties have not executed the same counterpart. Signatures
provided by facsimile transmission or in AdobeTM Portable Document Format (PDF) sent by electronic mail will be deemed to be original signatures. 

 IN WITNESS WHEREOF, each Party has caused this Agreement to be duly executed by its authorized
representative under seal, in duplicate on the Amendment Effective Date. 
  

	
	NAVIRE PHARMA, INC.
	
	     /s/ Michael Henderson

	Name: Michael Henderson
	Title: CBO
	
	LIANBIO LICENSING LLC
	
	     /s/ Konstantin Poukalov

	Name: Konstantin Poukalov
	Title: Director
	
	LIANBIO
	
	     /s/ Konstantin Poukalov

	Name: Konstantin Poukalov
	Title: Director

 SIGNATURE PAGE OF THE THIRD AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}]]